Meeting
2022 ASCO Genitourinary Cancers Symposium
Phase Ib study of avelumab and taxane based chemotherapy in platinum-refractory or ineligible metastatic urothelial cancer (AVETAX study).
Authors
Rohan Garje
Department of Internal Medicine, Division of Hematology/Oncology, University of Iowa, Iowa City, IA
Rohan Garje , Vignesh T. Packiam , Amy Koski , Mohammed M. Milhem , Michael A. O'Donnell , Yousef Zakharia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03575013
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 503)
DOI
10.1200/JCO.2022.40.6_suppl.503
Abstract #
503
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).
First Author: Michal Sternschuss
Poster
2024 ASCO Genitourinary Cancers Symposium
Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment.
First Author: Philippe Barthelemy
Poster
2024 ASCO Genitourinary Cancers Symposium
Trends over time in the proportion of sequential treatment and overall survival in patients with metastatic urothelial carcinoma in real-world practice.
First Author: Shoma Yamamoto
Poster
2023 ASCO Genitourinary Cancers Symposium
Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
First Author: Scott T. Tagawa